Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
ATXS Stock Chart & Stats
$12.60
-$0.31(-3.58%)
At close: 4:00 PM EST
$12.60
-$0.31(-3.58%)
Day’s Range― - ―
52-Week Range$3.56 - $12.60
Previous CloseN/A
Volume35.54K
Average Volume (3M)2.87M
Market Cap
$711.08M
Enterprise Value$151.82M
Total Cash (Recent Filing)$259.18M
Total Debt (Recent Filing)$4.77M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 12, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding56,434,895
10 Day Avg. Volume7,673,980
30 Day Avg. Volume2,867,309
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$24.83Price Target Upside97.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
AcquisitionBioCryst agrees to acquire Astria for a mix of cash and stock representing an implied value of $13/share, representing a premium of ~53% over Astria's closing share price.
Market ExpansionBioCryst intends to expand HAE franchise by adding ATXS's Phase 3 long-acting injectable navenibart into its HAE portfolio.
Product SynergyBioCryst's ability to leverage its existing commercial infrastructure means both investors and the HAE community will benefit from the combined company expertise and asset profiles.
Bears Say
Astria Therapeutics News
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $3.56 and its highest was $12.60 in the past 12 months.
What is Astria Therapeutics’s market cap?
Astria Therapeutics’s market cap is $711.08M.
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 12 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.588 by $0.018.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -0.39.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 56,434,895 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.588. Following the earnings report the stock price went up 3.308%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Currently, no hedge funds are holding shares in ATXS
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.83 (97.06% Upside)
$24.83 (97.06% Upside)
Blogger Sentiment
Bullish
ATXS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 54.4%
Last 30 Days ▲ 54.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.05%
12-Months-Change
Fundamentals
Return on Equity
-38.49%
Trailing 12-Months
Asset Growth
-23.39%
Trailing 12-Months
Company Description
Astria Therapeutics
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
ATXS Stock 12 Month Forecast
Average Price Target
$24.83
▲(97.06% Upside)
Technical Analysis
Autolus Therapeutics
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
PureTech Health
―
Monte Rosa Therapeutics
―
Ownership Overview
0.47%
Insiders
15.34% Mutual Funds
<0.01% Other Institutional Investors
76.16% Public Companies and Individual Investors